Effect of CCR2-V64I on the Susceptibility of Patients to Cancer

Table 1

The detailed characteristics of included studies.

Authors (year)	Country	Ethnicity	Cancer type	Case/control	Cases			Controls			Genotyping method	Source of controls	HWE
					GG	GA	AA	GG	GA	AA
Zafiropoulos (2004)	Greece	European	BC^a	264/211	221	38	5	154	50	7	PCR-RFLP	PB	0.251
Zafiropoulos (2004)	Greece	European	BC^b	68/148	51	16	1	115	33	0	PCR-RFLP	PB	0.127
Zafiropoulos (2004)	Greece	European	SC	110/362	74	32	4	271	87	4	PCR-RFLP	PB	0.303
Ivansson (2007)	Sweden	European	CC	1294/286	1054	228	12	217	61	8	PCR	HB	0.153
Liou (2008)	Taiwan	Asian	GC	177/217	109	59	9	138	71	8	PCR-RFLP	HB	0.760
Vázquez-Lavista (2009)	Mexico	Others	BC^b	47/126	28	19	0	74	43	9	PCR-RFLP	PB	0.432
Attar (2010)	Turkey	Asian	EC	50/211	34	9	7	153	50	8	PCR-RFLP	HB	0.139
Bracci (2010)	USA	American	NHL	475/744	391	81	3	610	131	3	PCR	PB	0.147
Chatterjee (2010)	South Africa	African	CC	106/305	24	81	1	189	112	4	PCR-SSP	HB	0.005
Chatterjee (2010)	South Africa	Mixed	CC	340/1073	78	255	7	704	356	13	PCR-SSP	HB	<0.001
Narter (2010)	Turkey	Asian	BC^b	72/76	39	23	10	59	15	2	PCR-RFLP	PB	0.394
Yeh (2010)	Taiwan	Asian	HCC	102/344	66	31	5	276	61	7	PCR-RFLP	HB	0.106
Chen (2011)	Taiwan	Asian	OC^a	216/344	142	67	7	276	61	7	PCR-RFLP	HB	0.106
Bektas-Kayhan (2012)	Turkey	Asian	OC^a	129/140	88	35	6	112	24	4	PCR-RFLP	HB	0.07
Kucukgergin (2012)	Turkey	Asian	PC	156/152	101	44	11	120	30	2	PCR-RFLP	HB	0.936
Singh (2012)	India	Asian	BC^b	200/200	128	62	10	126	70	4	PCR-RFLP	HB	0.104
Kucukgergin (2012)	Turkey	Asian	BC^b	142/197	97	37	8	159	35	3	PCR-RFLP	HB	0.508
Liu (2013)	China	Asian	RCC	416/458	240	103	73	313	110	35	PCR-RFLP	HB	<0.001
Zambra (2013)	Brazil	Others	PC	135/118	107	26	2	88	27	3	PCR-RFLP	HB	0.596
Ding (2013)	China	Asian	CC	40/60	11	5	24	23	19	18	PCR-SSP	HB	0.005
Mandal (2015)	India	Asian	PC	195/250	113	75	7	137	98	15	PCR-RFLP	HB	0.646
Rafrafi (2015)	Tunisia	Others	NSCLC	170/225	105	52	13	169	52	4	PCR-RFLP	PB	1.000
Banin-Hirata (2016)	Brazil	Others	BC^a	118/180	91	25	2	140	37	3	PCR-RFLP	NA	0.760
Bagci (2016)	Turkey	Asian	LC	65/57	47	16	2	39	16	2	PCR-RFLP	NA	0.822
Walczak (2017)	Poland	Others	CRC	214/144	157	55	2	108	34	2	PCR-RFLP	PB	0.712
Yildirim (2017)	Turkey	Asian	OC^b	43/45	19	21	3	27	15	3	PCR	HB	0.647

BC^a: breast cancer; BC^b: bladder cancer; SC: skin cancer; CC: cervical cancer; GC: gastric cancer; EC: endometrial cancer; NHL: non-hodgkin lymphoma; HCC: hepatocellular carcinoma; OC^a: oral cancer; PC: prostate cancer; RCC: renal cell carcinoma; NSCLC: non-small cell lung cancer; LC: lung cancer; CRC: colorectal cancer; OC^b: ovarian cancer; NA: not available; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCR: polymerase chain reaction; PCR-SSP: polymerase chain reaction-sequence-specific primers; PB: population-based study; HB: hospital-based study.